Originally published in Chemistry Europe.
A stereocontrolled and modular total synthesis of Lipoxin B4 (LXB4) was developed in 25% overall yield in just 10 steps. Previously reported syntheses to date were generally low yielding, together with long synthetic routes and lack full spectral characterization for LXB4. Download the article to learn more.
Tags: Articles & Whitepapers
Date: 7th - 9th June 2022
Location: Amsterdam, Netherlands | Hybrid event
Attending: Thierry Wurch, Barbara Bachler-Konetzki, Dan Ozanne
Evotec will be attending and showcasing its research at Antibody Engineering & Therapeutics Europe along with our Just-Evotec Biologics colleagues.
Thierry Wurch, Ph.D., SVP, Integrated Biologics Development at Evotec
If you wish to meet with us in Amsterdam, get in touch via the form below. We will be happy to arrange a meeting.
Tags: Events, Just Evotec Biologics
Date: 13-16 November 2022
Location: Gaylord Rockies Resort & Convention Center, Aurora CO
Attendees: David Cerny & Chris Strock
Presentation: Christopher Strock - Prediction of Chemotherapy-Induced Peripheral Neuropathy using Neurite Outgrowth: Comparison of Sensitivity using rat cortical neurons, IPSC derived human neurons, and Rat Dorsal Root Ganglion Neurons
Join David Cerny & Chris Strock on the Tox Hunt!
Learn more about ACT’s 43rd Annual Meeting and ACT Expo Live!
Date: 3-5 October 2022
Location: Hôtel Mövenpick Amsterdam City Centre, Piet Heinkade 11, 1019 BR Amsterdam, Netherlands
Attendees: Tim Potter, Oksana Nikolayenko , Rachel Upcott Gill and Phil Butler
Poster Presentation: 'Comparing basic static models for predicting clinical CYP3A4 induction risk' - Rachel Upcott Gill
Learn More about DMDG/GMP/SPS Joint Meeting
Date: 28-29 September 2022
Location: Malmo, Sweden
Attendees: Daniel Gliesche
Date: 24th May 2022
Location: Foster City Crowne Plaza, San Francisco
Attendee: David Cerny
Read more about Northern California Regional Chapter Spring Symposium 2022 Rise to the Next Normal
Date: 12 - 13 May 2022
Location: Wequassett Resort & Golf Club in Chatham, MA on Cape Cod
Attending: Jon Gunther, Cenk Cetin
Evotec will be sponsoring the Convergence Forum 2022. Our Vice President Business Development, Just – Evotec Biologics, Jon Gunther, will be a speaker on "The bright future of biologics: How design & manufacturing can drive innovation, lower costs & broaden access" on Friday 13th May at 10:15am in mainstage session: How New Pressures are Changing Biopharma Manufacturing.
If you wish to meet with our experts at Convergence, get in touch via the form below, we will be happy to arrange a meeting.
Tags: Events, Evotec, Just Evotec Biologics
Autotaxin (ATX) is a secreted glycoprotein that hydrolyzes lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA). LPA signalling directly modulates tumour cell function and contributes to the development of the fibrotic tumour microenvironment, resulting in reduced host immunity and impaired response to therapy.
iOnctura, a clinical-stage oncology company, based in Switzerland (Genève), targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, has developed a potent and orally available autotaxin inhibitor, IOA-289, as a novel treatment for pancreatic cancer and other highly fibrotic tumours.
The first Phase I clinical study in healthy volunteers has been successfully completed. Evotec is very proud to have actively contributed in conducting the trial and analyzing the results that led to the achievement of this exciting goal.
Read the poster presented by iOnctura at the ESMO Immuno-Oncology Congress held in December 2021 to learn more about IOA-289 and its activity as autotaxin inhibitor. IOA-289 was also presented by iOnctura at the recently held AACR Annual Meeting in New Orleans.
Tags: Oncology, Posters, Clinical Development